MSD’s decision to ditch its £1bn London research center has left a gaping void in the UK’s scientific landscape and its economic ambitions. The move is not just a financial loss but a symbolic blow, undermining the government’s narrative of a thriving, post-Brexit life sciences sector.
This “£1bn hole” is a stark manifestation of a wider industry sentiment. It follows warnings from executives across the sector that the UK’s commercial environment is becoming untenable. As one Sanofi chief put it, the country has become a “terrible place to sell medicines,” making massive R&D investments like MSD’s unjustifiable.
The loss of the facility has a domino effect. It removes a potential anchor for a new life sciences cluster in London, costs thousands of potential high-skilled jobs, and sends a negative signal to other potential investors. It is now being followed by investment pauses from other key players like Eli Lilly.
Filling this void will require more than just finding a new tenant for the site. It will demand a fundamental shift in government policy to address the root causes of MSD’s departure. The industry is looking for a new deal on pricing and spending that can make the UK an attractive place to invest a billion pounds again.